Claris Lifesciences Ltd, an Ahmedabad based company for contract manufacturing and research has filed an abbreviated new drug application (ANDA) for fluconazole in the US. Fluconazole is a class of antifungals called triazoles and is used to treat fungal infections, including yeast infections of the vagina, mouth, throat, esophagus, abdomen, lungs, blood and other organs.

"We have developed fluconazole in Nacl 0.9%, in injection and tablet form. It is an antifungal that works by slowing the growth of fungi causing infection. Fluconazole can also be used to treat meningitis caused by fungus and prevent yeast infections in patients who are likely to be infected. At present it is targeted for the international market in UK and several European countries," said company sources.

Also, first order of propofol has been supplied to Australia. The company has sent eight dossier submissions to regulated markets including UK and many European countries.

"We have received the first ever direct purchase order from a prestigious international aid agency, which is a regional office of WHO," sources added.

The company has achieved revenues of Rs. 208 crore during the nine months ended September 2005 as against Rs. 203 crore. The company recorded 49 per cent growth in exports as compared to 2004.

Claris manufactures and markets product delivery systems in the areas of nutrition, critical care and renal care through innovative drugs such as propofol, amino acids, fat emulsion, non-PVC double chambered bags for nutrition products, parenterals and injectables in glass bottles, PVC and non-PVC bags and vials. The types of products and technologies covered include, drug delivery, generics, pharmaceuticals, therapeutics and nutritionals/vitamins.